FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
The Journal of veterinary medical science2009; 71(11); 1439-1448; doi: 10.1292/jvms.001439

Equine herpesvirus type 1 mutant defective in glycoprotein E gene as candidate vaccine strain.

Abstract: An equine herpesvirus type 1 (EHV-1) mutant, DeltagE, defective in glycoprotein E (gE) was evaluated as a modified live virus (MLV) vaccine. Colostrum-deprived Thoroughbred foals inoculated intranasally (i.n.) or intramuscularly (i.m.) with DeltagE did not exhibit any clinical signs of respiratory disease except for a mild nasal discharge in 1 i.n. inoculated foal on Days 1 and 3 post-infection. In contrast, the intranasal inoculation of foals with the revertant of DeltagE resulted in biphasic pyrexia, mucopurulent nasal discharge and swelling of submandibular lymph nodes. These results indicated that gE plays an important role as regards EHV-1 virulence in horses. The ability of DeltagE to protect against wild type EHV-1 challenge infection was assessed using i.m. vaccinated foals. Foals inoculated twice i.m. with 10(5) or 10(6) plaque-forming units (pfu) of DeltagE at an interval of 3 weeks exhibited no clinical evidence of local inflammation, respiratory disease or deleterious systemic responses. Remarkable increases in SN antibody titer to EHV-1 were observed in all vaccinated foals after the 2nd inoculation with DeltagE. Following a wild type EHV-1 challenge infection, vaccinated foals showed milder clinical symptoms than foals vaccinated with a placebo. Specifically, 1 of 3 foals vaccinated with 10(6) pfu of DeltagE exhibited no clinical symptoms other than a mild nasal discharge for 1 day. Additionally, the virus load of nasal shedding and viremia were reduced by vaccination. These results suggest that DeltagE would be a good candidate as an MLV vaccine.
Get Full Text
Publication Date: 2009-12-05 PubMed ID: 19959893DOI: 10.1292/jvms.001439Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Controlled Clinical Trial
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explores the potential use of a specially modified equine herpesvirus type 1 (EHV-1) that lacks the glycoprotein E (gE) gene, termed DeltagE, as a live vaccine in Thoroughbred foals. The results indicate that the DeltagE variant plays a critical role in EHV-1’s virulence, and also appears to offer protection against wild type EHV-1 infection.

Experiment Methodology

  • The researchers investigated the DeltagE mutant of EHV-1 through intranasally (i.n.) and intramuscularly (i.m.) inoculating colostrum-deprived Thoroughbred foals.
  • The animals did not show significant signs of respiratory disease, barring a mild nasal discharge in one foal inoculated nasally.
  • For comparison, foals were also intranasally inoculated with a DeltagE revertant, which caused biphasic pyrexia, mucopurulent nasal discharge and swelling of the submandibular lymph nodes, symptoms commonly associated with EHV-1.

Findings and Implications

  • The contrasting responses to DeltagE and its revertant indicate that the gE gene is crucial for EHV-1’s virulence, i.e., its ability to cause disease.
  • The potential of DeltagE to protect against wild type EHV-1 infection was tested by twice injecting foals intramuscularly with different doses of DeltagE, with a three-week interval between doses.
  • Foals given this treatment showed no signs of local inflammation, respiratory disease or harmful systemic responses, indicating that DeltagE is safe.
  • All vaccinated foals experienced significant increases in SN (serum neutralization) antibody titer to EHV-1 after the second inoculation, suggesting that the DeltagE vaccine effectively stimulates an immune response.
  • When challenged with a wild type EHV-1 infection after vaccination, the symptoms were milder in the foals given DeltagE than in those given a placebo. Further, one foal showed minimal symptoms, and the virus load in nasal shedding and the bloodstream was reduced, pointing to the vaccine’s potential efficacy.

Conclusion

  • The research suggests that DeltagE is a potential candidate for a modified live virus (MLV) vaccine against EHV-1

Cite This Article

APA
TSUJIMURA K, SHIOSE T, YAMANAKA T, NEMOTO M, KONDO T, MATSUMURA T. (2009). Equine herpesvirus type 1 mutant defective in glycoprotein E gene as candidate vaccine strain. J Vet Med Sci, 71(11), 1439-1448. https://doi.org/10.1292/jvms.001439

Publication

The Journal of veterinary medical science
ISSN: 0916-7250
NlmUniqueID: 9105360
Country: Japan
Language: English
Volume: 71
Issue: 11
Pages: 1439-1448

Researcher Affiliations

TSUJIMURA, Koji
  • Epizootic Research Center, Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan. koji_tsujimura@jra.go.jp
SHIOSE, Tomoki
    YAMANAKA, Takashi
      NEMOTO, Manabu
        KONDO, Takashi
          MATSUMURA, Tomio

            MeSH Terms

            • Administration, Intranasal
            • Animals
            • Gene Expression Regulation, Viral
            • Herpesviridae Infections / prevention & control
            • Herpesviridae Infections / veterinary
            • Herpesvirus 1, Equid / genetics
            • Herpesvirus 1, Equid / immunology
            • Horse Diseases / prevention & control
            • Horses
            • Injections, Intramuscular
            • Mutation
            • Viral Envelope Proteins / genetics
            • Viral Envelope Proteins / immunology
            • Viral Vaccines / administration & dosage
            • Viral Vaccines / adverse effects
            • Viral Vaccines / immunology

            Citations

            This article has been cited 10 times.
            1. Ning Y, Huang Y, Wang M, Cheng A, Yang Q, Wu Y, Tian B, Ou X, Huang J, Mao S, Sun D, Zhao X, Zhang S, Gao Q, Chen S, Liu M, Zhu D, Jia R. Alphaherpesvirus glycoprotein E: A review of its interactions with other proteins of the virus and its application in vaccinology. Front Microbiol 2022;13:970545.
              doi: 10.3389/fmicb.2022.970545pubmed: 35992696google scholar: lookup
            2. Lee Y, Maes RK, Kruger JM, Kiupel M, Giessler KS, Soboll Hussey G. Safety and Efficacy of Felid Herpesvirus-1 Deletion Mutants in Cats. Viruses 2021 Jan 22;13(2).
              doi: 10.3390/v13020163pubmed: 33499363google scholar: lookup
            3. Bannai H, Tsujimura K, Nemoto M, Ohta M, Yamanaka T, Kokado H, Matsumura T. Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine. BMC Vet Res 2019 Aug 6;15(1):280.
              doi: 10.1186/s12917-019-2036-0pubmed: 31387602google scholar: lookup
            4. Maes R. Felid herpesvirus type 1 infection in cats: a natural host model for alphaherpesvirus pathogenesis. ISRN Vet Sci 2012;2012:495830.
              doi: 10.5402/2012/495830pubmed: 23762586google scholar: lookup
            5. Mahmoud HY, Andoh K, Hattori S, Terada Y, Noguchi K, Shimoda H, Maeda K. Characterization of glycoproteins in equine herpesvirus-1. J Vet Med Sci 2013 Oct;75(10):1317-21.
              doi: 10.1292/jvms.13-0168pubmed: 23748975google scholar: lookup
            6. Pradhan SS, Balena V, Bera BC, Anand T, Khetmalis R, Madhwal A, Kandasamy S, Pavulraj S, Bernela M, Mor P, Tripathi BN, Virmani N. Multiple Gene Deletion Mutants of Equine Herpesvirus 1 Exhibit Strong Protective Efficacy Against Wild Virus Challenge in a Murine Model. Vaccines (Basel) 2025 Jan 8;13(1).
              doi: 10.3390/vaccines13010045pubmed: 39852824google scholar: lookup
            7. Nishimura F, Fukushi N, Sakai H, Fukushi H. Attenuation of the neuropathogenic equine herpesvirus type 1 strain Ab4p in hamsters by a single amino acid mutation (D752N) in viral DNA polymerase ORF30. J Vet Med Sci 2024 Dec 1;86(12):1273-1278.
              doi: 10.1292/jvms.24-0338pubmed: 39384384google scholar: lookup
            8. Hu Y, Wu G, Jia Q, Zhang B, Sun W, Sa R, Zhang S, Cai W, Jarhen, Ran D, Liu J. Development of a live attenuated vaccine candidate for equid alphaherpesvirus 1 control: a step towards efficient protection. Front Immunol 2024;15:1408510.
              doi: 10.3389/fimmu.2024.1408510pubmed: 39021566google scholar: lookup
            9. Pusterla N, Dorman DC, Burgess BA, Goehring L, Gross M, Osterrieder K, Soboll Hussey G, Lunn DP. Viremia and nasal shedding for the diagnosis of equine herpesvirus-1 infection in domesticated horses. J Vet Intern Med 2024 May-Jun;38(3):1765-1791.
              doi: 10.1111/jvim.16958pubmed: 38069548google scholar: lookup
            10. Osterrieder K, Dorman DC, Burgess BA, Goehring LS, Gross P, Neinast C, Pusterla N, Hussey GS, Lunn DP. Vaccination for the prevention of equine herpesvirus-1 disease in domesticated horses: A systematic review and meta-analysis. J Vet Intern Med 2024 May-Jun;38(3):1858-1871.
              doi: 10.1111/jvim.16895pubmed: 37930113google scholar: lookup
            Subscribe to our newsletter
            Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.